Tirzepatide
Dual GIP/GLP-1 receptor agonist for weight management and metabolic health
Clinical Research Score: 5/5 — FDA-approved (Mounjaro/Zepbound) with large SURMOUNT randomized trials showing substantial weight loss.
Categories: Weight Loss / Metabolic
What is Tirzepatide?
Tirzepatide represents the next evolution beyond semaglutide — and the results have been nothing short of remarkable. Clinical trials showed participants losing up to 20% of their body weight, numbers that were previously considered unachievable with medication alone.
People describe the same silencing of food noise that semaglutide provides, but often more profound. Appetite drops dramatically. Cravings disappear. But what sets tirzepatide apart is the dual mechanism — it targets two appetite-controlling pathways instead of one, providing more comprehensive metabolic improvement.
Blood sugar control is exceptional. Body composition changes are visible and sustained. Many people who plateaued on GLP-1-only medications report renewed progress with tirzepatide. For those seeking maximum weight loss and metabolic improvement, it currently represents one of the most powerful options available.
How Tirzepatide works
Tirzepatide is a dual-agonist — it activates both GIP and GLP-1 receptors simultaneously. GLP-1 activation suppresses appetite, slows gastric emptying, and improves insulin secretion. GIP activation provides additional insulin sensitization and may help maintain lean body mass during weight loss. The dual mechanism creates a synergistic effect — the combined metabolic improvement is greater than what either pathway alone could achieve.
Scientific overview
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This dual mechanism provides superior glycemic control and weight loss compared to selective GLP-1 agonists alone. It has shown unprecedented efficacy in clinical trials, with participants achieving up to 20% body weight reduction.
Dosing
- Starting dose: 2.5 mg per week
- Common dosage range: 2.5-15 mg per week (titrated up)
- Administration: Subcutaneous
- Half-life: ~5 days
- Frequency: 1x per week